ZURA BIO LIMITED Additional Paid in Capital
ZURA BIO LIMITED (ZURA) had Additional Paid in Capital of $472.15 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital $472.15M.
- 2026-03-31: Additional Paid in Capital $465.66M.
- 2025-12-31: Additional Paid in Capital $326.08M.
- 2025-09-30: Additional Paid in Capital $315.61M.
| Period end | Additional Paid in Capital |
|---|---|
| 2026-06-30 | $472.15M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $465.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $326.08M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $315.61M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $315.23M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $311.53M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $302.70M 10-K · filed 2026-03-19 |
| 2024-09-30 | $295.31M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $278.09M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $172.25M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $162.82M 10-K · filed 2025-03-25 |
| 2023-09-30 | $158.23M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $155.65M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $69.70M 10-Q · filed 2023-05-12 |
| 2021-06-30 | $24.66K 10-Q · filed 2021-08-27 |
| 2021-03-31 | $24.57K 10-Q · filed 2021-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |